bluebird bio, Inc. - BLUE Operating Margin

bluebird bio, Inc. - graphic logo of issuer BLUE

The high macro-resilience of the healthcare sector is coupled here with complex logistics costs and production barriers for bluebird bio, Inc. (BLUE). The operating margin trend demonstrates current resource management efficiency, where -202.50 expresses the metric's value today. Unique developments in gene therapy, which provide complete cures for patients with hereditary blood pathologies, serve as the foundation for success.

bluebirdbio.com (BLUE): Return on Sales by Operating Profit from 07/04/2022 to 06/07/2025

BLUE (bluebird bio, Inc.): analytical breakdowns and indicator data

- stock quotes and analyst forecast:
Summary company analysis:BLUE, Bluebird Bio
Brand item of bluebird bio, Inc

For bluebird bio, Inc. (BLUE), which holds exclusive gene therapy patents within the FDA's stringent regulatory framework, the current operating margin serves as an indicator of the monetization of its technological advantage. This ratio is calculated as operating income divided by revenue, demonstrating the share of net income from core operations before taxes and interest payments, which allows for an assessment of the business's internal efficiency and its resilience to market volatility.

Key competitors

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|TSHA: Operating Profit Ratio|Operating Profitability uniQure Pharma|MGTX - Operating Profitability Margin|Operating Margin RGNX|Operating Profitability SLDB (Solid Biosciences)|Ocugen Corp - Operating Sales Margin|PACB: Return on Sales by Operating Profit|benitec.com - Operating Margin|DSGN - Operating Margin|RCKT: Operating Margin|FDMT (4D Molecular Therapeutics Inc) - Operating Profitability|Operating Sales Margin LXEO|Operating Profitability KRRO|Operating Margin EDIT|SLN - Operating Return on Sales|Operating Margin PRQR (ProQR)|CDXS - Operating Sales Margin|Sangamo Therapeutics Inc. - Operating Margin|NAUT - Operating Margin|MGX: Operating Margin|Operating Sales Margin Precision BioSciences, Inc.|GBIO (Generation Bio) - Operating Margin|Boundless Bio Inc. (BOLD) - Profitability of Operations|Operating Sales Margin XCUR (exicuretx.com)|Imunon Inc - Return on Sales by Operating Profit|Operating Margin PHIO (Phio Pharmaceuticals Corp)|Operating Profit Rate MBIO|RNAZ - Operating Profitability|Operating Profit Rate BNGO (bionanogenomics.com)|Applied DNA Sciences (APDN) - Operating Profitability|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability